Daptomycin versus placebo as an adjunct to beta-lactam therapy in the treatment of Staphylococcus aureus bacteremia: study protocol for a randomized controlled trial

Trials
Matthew P ChengTodd C Lee

Abstract

Staphylococcus aureus bacteremia is associated with significant morbidity and mortality. To treat this infection, the current standard of care includes intravenous anti-staphylococcal beta-lactam antibiotics and obtaining adequate source control. Combination therapy with an aminoglycoside or rifampin, despite early promise, can no longer be routinely recommended due to an absence of proven benefit and risk of harm. Daptomycin is a rapidly acting bactericidal antibiotic that is approved for the treatment of Staphylococcus aureus bacteremia as monotherapy but has not been shown to be superior to the current standard of care. As demonstrated in vitro, the addition of daptomycin to beta-lactam therapy may result in enhanced anti-staphylococcal activity. Our objective is to assess the efficacy and safety of prescribing the combination of daptomycin with cefazolin or cloxacillin for the treatment of methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia in adults. We hypothesize that adjunctive therapy with daptomycin will reduce the duration of bacteremia in this population. The DASH-RCT trial is a randomized, double blind, placebo-controlled trial designed per the Standard Protocol Items: Recommendation for Interventional ...Continue Reading

Associated Clinical Trials

References

Jul 15, 1994·Statistics in Medicine·D L DeMets, K K Lan
Apr 17, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·L A MermelUNKNOWN Society for Healthcare Epidemiology of America
Jun 14, 2003·The Journal of Antimicrobial Chemotherapy·S S RichterG V Doern
Jul 27, 2004·Antimicrobial Agents and Chemotherapy·Kenneth H Rand, Herbert J Houck
Feb 12, 2005·The Journal of Antimicrobial Chemotherapy·Judith N SteenbergenFrancis P Tally
Aug 18, 2006·The New England Journal of Medicine·Vance G FowlerUNKNOWN S. aureus Endocarditis and Bacteremia Study Group
Jan 30, 2007·Hemodialysis International·Laura TroidleFredric Finkelstein
Jun 6, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Leonard A MermelDavid K Warren
Nov 18, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Wissam I El AtrouniLarry M Baddour
Jun 22, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Abhay DhandGeorge Sakoulas
Jun 29, 2012·The New England Journal of Medicine·Duk-Hyun KangDae-Won Sohn
Dec 25, 2013·Antimicrobial Agents and Chemotherapy·George SakoulasVictor Nizet
Feb 24, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Anthony D BaiAndrew M Morris
Sep 10, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Joshua S DavisUNKNOWN Australasian Society for Infectious Diseases Clinical Research Network
Sep 16, 2015·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Yoona RheeKyle J Popovich
Sep 17, 2015·Circulation·Larry M BaddourUNKNOWN American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular
Feb 14, 2016·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·D YahavL Leibovici
Mar 1, 2016·The American Journal of Medicine·Matthew P ChengTodd C Lee
Apr 1, 2016·Trials·Steven Y C TongUNKNOWN CAMERA2 study group and the Australasian Society for Infectious Diseases Clinical Research Network
Apr 6, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jennifer S McDanelMarin L Schweizer
Dec 19, 2017·Lancet·Guy E ThwaitesUNKNOWN United Kingdom Clinical Infection Research Group (UKCIRG)

❮ Previous
Next ❯

Citations

Nov 20, 2020·Open Forum Infectious Diseases·Guillaume Butler-LaporteTodd C Lee
Mar 12, 2021·Frontiers in Microbiology·Gabrielle S DijksteelBouke K H L Boekema
Jul 16, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Matthew P ChengTodd C Lee
Aug 28, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Matthew P ChengTodd C Lee

❮ Previous
Next ❯

Software Mentioned

R
Etest®
SAS
REDCap
STATA

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Anaphylaxis

Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death.